Immunotherapy of multiple sclerosis: the end of the beginning.

[1]  Lawrence Steinman,et al.  Multiple sclerosis: a two-stage disease , 2001, Nature Immunology.

[2]  P. Fontoura,et al.  Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway. , 2001, Immunity.

[3]  Marco Rovaris,et al.  Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study , 2001, The Lancet.

[4]  G. Ebers.  Preventing multiple sclerosis? , 2001, The Lancet.

[5]  A. Evans,et al.  Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial , 2000, Nature Medicine.

[6]  S. Zamvil,et al.  Specific immunotherapy: One size does not fit all , 2000, Nature Medicine.

[7]  J. Frank,et al.  Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand , 2000, Nature Medicine.

[8]  J H Simon,et al.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.

[9]  G. Trinchieri,et al.  Inhibition of IL-12 Production in Human Monocyte-Derived Macrophages by TNF1 , 2000, The Journal of Immunology.

[10]  L. Steinman,et al.  Assessment of Animal Models for MS and Demyelinating Disease in the Design of Rational Therapy , 1999, Neuron.

[11]  Jacqueline Palace,et al.  The effect of anti-α4 integrin antibody on brain lesion activity in MS , 1999, Neurology.

[12]  I. Weissman,et al.  Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[13]  G. Kollias,et al.  Chronic Tumor Necrosis Factor Alters T Cell Responses by Attenuating T Cell Receptor Signaling , 1997, The Journal of experimental medicine.

[14]  F. Barkhof,et al.  Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2 , 1996, Neurology.

[15]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[16]  J. W. Rose,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.

[17]  C. Raine,et al.  The adhesion molecule and cytokine profile of multiple sclerosis lesions , 1995, Annals of neurology.

[18]  R. Beck,et al.  The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. , 1993, The New England journal of medicine.

[19]  P. Duquette,et al.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .

[20]  F. Sánchez‐Madrid,et al.  Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin , 1992, Nature.

[21]  M. Sharief,et al.  Association between Tumor Necrosis Factor-α and Disease Progression in Patients with Multiple Sclerosis , 1991 .

[22]  G. Wong,et al.  TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination , 1998, Nature Medicine.

[23]  M. Feldmann,et al.  Role of cytokines in rheumatoid arthritis. , 1996, Annual review of immunology.